These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22876944)

  • 1. Anti-cancer targeting telomerase inhibitors: β-rubromycin and oleic acid.
    Mizushina Y; Takeuchi T; Sugawara F; Yoshida H
    Mini Rev Med Chem; 2012 Oct; 12(11):1135-43. PubMed ID: 22876944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of human telomerase by rubromycins: implication of spiroketal system of the compounds as an active moiety.
    Ueno T; Takahashi H; Oda M; Mizunuma M; Yokoyama A; Goto Y; Mizushina Y; Sakaguchi K; Hayashi H
    Biochemistry; 2000 May; 39(20):5995-6002. PubMed ID: 10821671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of telomerase by linear-chain fatty acids: a structural analysis.
    Oda M; Ueno T; Kasai N; Takahashi H; Yoshida H; Sugawara F; Sakaguchi K; Hayashi H; Mizushina Y
    Biochem J; 2002 Oct; 367(Pt 2):329-34. PubMed ID: 12121150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The biochemical mode of inhibition of DNA polymerase beta by alpha-rubromycin.
    Mizushina Y; Ueno T; Oda M; Yamaguchi T; Saneyoshi M; Sakaguchi K
    Biochim Biophys Acta; 2000 Oct; 1523(2-3):172-81. PubMed ID: 11042381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of human immunodeficiency virus-1 reverse transcriptase activity by rubromycins: competitive interaction at the template.primer site.
    Goldman ME; Salituro GS; Bowen JA; Williamson JM; Zink DL; Schleif WA; Emini EA
    Mol Pharmacol; 1990 Jul; 38(1):20-5. PubMed ID: 1695317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of heterocyclic azoles derivatives containing pyrazine moiety as potential telomerase inhibitors.
    Zhang YB; Wang XL; Liu W; Yang YS; Tang JF; Zhu HL
    Bioorg Med Chem; 2012 Nov; 20(21):6356-65. PubMed ID: 23018096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An efficient formal synthesis of the human telomerase inhibitor (+/-)-gamma-rubromycin.
    Rathwell DC; Yang SH; Tsang KY; Brimble MA
    Angew Chem Int Ed Engl; 2009; 48(43):7996-8000. PubMed ID: 19644991
    [No Abstract]   [Full Text] [Related]  

  • 8. A convergent total synthesis of the telomerase inhibitor (±)-γ-rubromycin.
    Wilsdorf M; Reissig HU
    Angew Chem Int Ed Engl; 2014 Apr; 53(17):4332-6. PubMed ID: 24623604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel platinum compound inhibits telomerase activity in vitro and reduces telomere length in a human hepatoma cell line.
    Furuta M; Nozawa K; Takemura M; Izuta S; Murate T; Tsuchiya M; Yoshida K; Taka N; Nimura Y; Yoshida S
    Int J Cancer; 2003 May; 104(6):709-15. PubMed ID: 12640677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation, biological activity, biosynthesis and synthetic studies towards the rubromycin family of natural products.
    Atkinson DJ; Brimble MA
    Nat Prod Rep; 2015 Jun; 32(6):811-40. PubMed ID: 25798711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of human telomerase inhibitors having the core of N-acyl-4,5-dihydropyrazole with anticancer effects.
    Xiao X; Ni Y; Jia YM; Zheng M; Xu HF; Xu J; Liao C
    Bioorg Med Chem Lett; 2016 Mar; 26(6):1508-1511. PubMed ID: 26883149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomeres, telomerase and cancer: is the magic bullet real?
    Sharma HW; Maltese JY; Zhu X; Kaiser HE; Narayanan R
    Anticancer Res; 1996; 16(1):511-5. PubMed ID: 8615664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural and pharmacological regulation of telomerase.
    Mergny JL; Riou JF; Mailliet P; Teulade-Fichou MP; Gilson E
    Nucleic Acids Res; 2002 Feb; 30(4):839-65. PubMed ID: 11842096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isothiazolone derivatives selectively inhibit telomerase from human and rat cancer cells in vitro.
    Hayakawa N; Nozawa K; Ogawa A; Kato N; Yoshida K; Akamatsu Ki; Tsuchiya M; Nagasaka A; Yoshida S
    Biochemistry; 1999 Aug; 38(35):11501-7. PubMed ID: 10471302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity.
    Rankin AM; Faller DV; Spanjaard RA
    Anticancer Drugs; 2008 Apr; 19(4):329-38. PubMed ID: 18454043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telomerase inhibition as cancer therapy.
    Saretzki G
    Cancer Lett; 2003 May; 194(2):209-19. PubMed ID: 12757979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomerase inhibitors: a patent review (2010-2015).
    Man RJ; Chen LW; Zhu HL
    Expert Opin Ther Pat; 2016 Jun; 26(6):679-88. PubMed ID: 27104627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dihydropyrazole derivatives as telomerase inhibitors: Structure-based design, synthesis, SAR and anticancer evaluation in vitro and in vivo.
    Wang Y; Cheng FX; Yuan XL; Tang WJ; Shi JB; Liao CZ; Liu XH
    Eur J Med Chem; 2016 Apr; 112():231-251. PubMed ID: 26900656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of telomerase inhibitors for the treatment of cancer.
    Cairns D; Anderson RJ; Perry PJ; Jenkins TC
    Curr Pharm Des; 2002; 8(27):2491-504. PubMed ID: 12369943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Telomere and telomerase in human cancer].
    Hiyama K; Hiyama E; Ishioka S; Yamakido M
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):196-201. PubMed ID: 9030230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.